Literature DB >> 25829521

Extending the quality and safety agenda from parenteral to oral chemotherapy.

Monika K Krzyzanowska1, Melanie Powis2.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25829521     DOI: 10.1200/JOP.2015.004002

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  5 in total

1.  Patient and provider perspectives on delivery of oral cancer therapies.

Authors:  Caitlin C Murphy; Simon J Craddock Lee; David E Gerber; John V Cox; Hannah M Fullington; Robin T Higashi
Journal:  Patient Educ Couns       Date:  2019-06-20

2.  High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.

Authors:  Rehana Jamani; Esther K Lee; Scott R Berry; Ronak Saluja; Carlo DeAngelis; Angie Giotis; Urban Emmenegger
Journal:  Eur J Clin Pharmacol       Date:  2016-08-25       Impact factor: 2.953

3.  Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.

Authors:  Gennaro A Paolella; Andrew D Boyd; Scott M Wirth; Sandra Cuellar; Neeta K Venepalli; Stephanie Y Crawford
Journal:  Pharmacy (Basel)       Date:  2018-03-08

4.  Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial.

Authors:  Caitlin C Murphy; Hannah M Fullington; David E Gerber; Isaac Alex Bowman; Maneka Puligandla; Janice P Dutcher; Robert S DiPaola; Naomi B Haas
Journal:  Cancer Med       Date:  2021-08-18       Impact factor: 4.452

5.  Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).

Authors:  Karen B Farris; Tiffany Cadwallader; Joel Farley; Katie Gatwood; Emily Mackler; Justin Gatwood
Journal:  Explor Res Clin Soc Pharm       Date:  2022-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.